Sales licenses of Agrylin & Effient transferred to respective Shire & Daiichi Sankyo

In the 2^nd half of the year, selling companies of the essential thrombocytosis therapy, ‘Agrylin’ and the antithrombotic therapy, ‘Effient,’ will be changed.

So far, Agrylin and Effient were sold by Yuhan Corporation and jointly Lilly Korea and Daiichi Sankyo Korea, respectively.

According to the distribution industry on the 30^th, Agrylin and Effient will be solely sold by Shire Pharmaceutica...